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Background: Evidence for an association between hospital volume and outcomes for liver surgery is
abundant. The current Dutch guideline requires a minimum volume of 20 annual procedures per centre.
The aim of this study was to investigate the association between hospital volume and postoperative
outcomes using data from the nationwide Dutch Hepato Biliary Audit.
Methods: This was a nationwide study in the Netherlands. All liver resections reported in the Dutch
Hepato Biliary Audit between 2014 and 2017 were included. Annual centre volume was calculated and
classified in categories of 20 procedures per year. Main outcomes were major morbidity (Clavien–Dindo
grade IIIA or higher) and 30-day or in-hospital mortality.
Results: A total of 5590 liver resections were done across 34 centres with a median annual centre volume
of 35 (i.q.r. 20–69) procedures. Overall major morbidity and mortality rates were 11⋅2 and 2⋅0 per cent
respectively. The mortality rate was 1⋅9 per cent after resection for colorectal liver metastases (CRLMs),
1⋅2 per cent for non-CRLMs, 0⋅4 per cent for benign tumours, 4⋅9 per cent for hepatocellular carcinoma
and 10⋅3 per cent for biliary tumours. Higher-volume centres performed more major liver resections,
and more resections for hepatocellular carcinoma and biliary cancer. There was no association between
hospital volume and either major morbidity or mortality in multivariable analysis, after adjustment for
known risk factors for adverse events.
Conclusion: Hospital volume and postoperative outcomes were not associated.
∗Members of the Dutch Hepato Biliary Audit Group are co-authors of this study and can be found under the heading
Collaborators
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Introduction
In an effort to reduce morbidity and mortality after com-
plex surgical procedures, hospital volume has become a
frequent subject of debate1–3. Higher caseload leads to
more experience for the entire surgical treatment team,
which could benefit clinical outcomes. In upper gastro-
intestinal surgery, the volume–outcome relationship
has been studied most extensively for oesophageal and
pancreatic surgery4–6.
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Mortality after oesophagectomy in low-volume centres
is at least twice that in high-volume centres4. Perioperative
mortality after pancreatoduodenectomy is also more than
twofold lower in centres undertaking more than 40 resec-
tions compared with five procedures annually5,6. In the
Netherlands, these studies have led to a minimum annual
case volume of at least 20 procedures per hospital for these
operations. Without extensive evidence, this threshold has
been extrapolated to hepatobiliary surgery, including liver
resection.
Liver surgery, however, is more heterogeneous, with
numerous different types of procedures and techniques for
various indications, all with their distinct characteristics
and risk factors for adverse outcomes. Procedures range
from laparoscopic peripheral wedge resection to extended
right liver resection with biliary reconstruction for peri-
hilar cholangiocarcinoma. Currently there are no data
to support the hospital volume standard of 20 resections
annually in the Netherlands. Although improvements in
perioperative care have reduced overall surgical morbid-
ity, liver surgery is done in an ageing and increasingly
co-morbid population, and is still associated with sub-
stantial risks7–15. Adequate risk stratification across all
liver surgery centres is essential to ensure optimal clinical
outcomes.
This study aimed to investigate the relationship between
hospital volume and postoperative outcomes after liver
surgery using data from the nationwide Dutch Hepato
Biliary Audit (DHBA) on all hepatobiliary resections per-
formed in the Netherlands.
Methods
This was a retrospective nationwide study of patients who
underwent liver surgery in the Netherlands. The Nether-
lands is a high-income country in Western Europe with
over 17 million inhabitants. Healthcare is arranged in 121
hospitals, including eight university hospitals and one com-
prehensive cancer centre. In the Netherlands, require-
ments for treating several tumours have been defined by
Stichting Oncologische Samenwerking (SONCOS), which
is a national establishment for multidisciplinary oncologi-
cal cooperation founded by the Dutch Societies of Surgi-
cal Oncology, Radiotherapy and Medical Oncology. Liver
tumours and liver surgery are included. These guidelines
are also endorsed by the government and all insurance
companies. They include structural requirements such as
24/7 availability of an interventional radiologist and two
skilled hepatobiliary surgeons, volume requirements for
resection (at least 20 resections have to be performed
annually) and mandatory participation in the audit. All
hepatobiliary procedures are included in the nationwide
DHBA. The present study included patients who had liver
surgery for any indication between 1 January 2014 and
31 December 2017. Patients who underwent exploratory
laparotomy because unresectable disease was discovered
during surgery, and those who underwent extrahepatic bil-
iary resection only were excluded. Patients with essential
data missing (type of tumour, type of procedure, hospital
information or operation date) were also excluded.
The study protocol was approved by the scientific com-
mittee of the DHBA. All data were handled anonymously.
The need for ethical approval and individual informed con-
sent was waived by the medical ethics committee.
Dutch Hepato Biliary Audit
The DHBA is part of the Dutch Institute of Clinical
Auditing and was initiated by the Dutch Liver Surgery
Working Group. The DHBA started in 2013 and since 1
January 2014 it has been a mandatory audit for all Dutch
centres performing liver surgery. The inclusion criteria
are any resection for any type of liver tumour. In 2015
the registration was extended to include all procedures for
biliary tumours, with the biliary tumour location specified.
Before 2015, patients with biliary tumours were classified
as unspecified, along with those who underwent liver
resection for biliary tumours other than perihilar or intra-
hepatic cholangiocarcinoma. Besides direct feedback on
potential errors in data entry using the online data form,
voluntary external data verification was carried out. Based
on this verification, data accuracy was considered adequate
for all audited centres. Further details of the audit have
been described elsewhere14.
Hospital volume
The total number of liver resections performed during the
study in each centre was recorded and the median number
of procedures annually was defined as the hospital volume.
In centres where liver surgery was discontinued during
the study interval (all owing to an annual procedural vol-
ume below 20), only the years in which liver surgery was
performed were used in the volume calculation. Extrahep-
atic biliary resections and exploratory laparotomies without
liver resection were not included in hospital volume cal-
culations. The annual hospital volume was classified into
fewer than 20, 20–39, 40–59, 60–79 and 80 ormore proce-
dures. For multivariable analyses, the 20–39 category was
used as reference because of the existing volume require-
ment of 20 resections annually.
Definitions
Major liver resection was defined as resection of at least
three adjacent Couinaud segments. All complications
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Table 1 Patient and treatment characteristics and outcomes according to hospital volume in the Dutch Hepato Biliary Audit between
2014 and 2017
Hospital volume (annual no. of liver resections)
<20
(n = 196)
20–39
(n = 866)
40–59
(n = 822)
60–79
(n = 1953)
≥80
(n = 1753) P†
Baseline characteristics
Age>70 years 75 (38⋅3) 345 (39⋅8) 295 (35⋅9) 600 (30⋅7) 444 (25⋅3) 0⋅035
Men 117 (59⋅7) 503 (58⋅1) 462 (56⋅2) 1146 (58⋅7) 947 (54⋅0) < 0⋅001
ASA fitness grade> III 26 (13⋅3) 199 (23⋅0) 133 (16⋅2) 363 (18⋅6) 302 (17⋅2) <0⋅001
BMI (kg/m2)* 26⋅9(4⋅4) 25⋅9(4⋅2) 26⋅2(4⋅6) 26⋅5(4⋅6) 26⋅1(4⋅5) 0⋅076‡
Charlson co-morbidity index score≥2 70 (35⋅7) 264 (30⋅5) 210 (25⋅5) 542 (27⋅8) 409 (23⋅3) <0⋅001
Preoperative liver disease 1 (0⋅5) 41 (4⋅7) 18 (2⋅2) 71 (3⋅6) 94 (5⋅4) <0⋅001
Previous liver surgery 23 (12⋅5) 149 (17⋅3) 122 (14⋅8) 272 (13⋅9) 206 (11⋅8) 0⋅003
Preoperative chemotherapy 16 (8⋅8) 180 (22⋅1) 150 (18⋅2) 295 (15⋅1) 483 (27⋅6) <0⋅001
Preoperative portal vein embolization 0 (0) 10 (3⋅2) 10 (1⋅2) 34 (1⋅7) 61 (3⋅5) <0⋅001
Type of tumour <0⋅001
Colorectal liver metastasis 166 (84⋅7) 723 (83⋅5) 649 (79⋅0) 1304 (66⋅8) 1004 (57⋅3)
Liver metastasis from other origin 11 (5⋅6) 34 (3⋅9) 61 (7⋅4) 146 (7⋅5) 150 (8⋅6)
Benign liver tumour 15 (7⋅7) 58 (6⋅7) 42 (5⋅1) 190 (9⋅7) 214 (12⋅2)
Hepatocellular carcinoma 4 (2⋅0) 36 (4⋅2) 55 (6⋅7) 201 (10⋅3) 254 (14⋅5)
Malignant tumour of biliary tract 0 (0) 15 (1⋅7) 15 (1⋅8) 112 (5⋅7) 131 (7⋅5)
Operative characteristics and outcomes
Major liver resection 29 (14⋅8) 130 (15⋅0) 240 (29⋅2) 432 (22⋅1) 549 (31⋅3) <0⋅001
Minimally invasive approach 17 (8⋅7) 259 (29⋅9) 140 (17⋅0) 488 (25⋅0) 198 (11⋅3) <0⋅001
Intraoperative ablation 7 (3⋅6) 109 (12⋅6) 161 (19⋅6) 292 (15⋅0) 289 (16⋅5) < 0⋅001
Simultaneous colorectal resection 36 (18⋅4) 112 (12⋅9) 92 (11⋅2) 144 (7⋅4) 139 (7⋅9) <0⋅001
Simultaneous other resection 70 (35⋅7) 185 (21⋅4) 118 (14⋅4) 306 (15⋅7) 207 (11⋅8) < 0⋅001
Biliary reconstruction 0 (0) 1 (0⋅1) 3 (0⋅4) 47 (2⋅4) 44 (2⋅5) <0⋅001
Complicated postoperative course 22 (11⋅2) 97 (11⋅2) 122 (14⋅8) 230 (11⋅8) 297 (16⋅9) <0⋅001
Major morbidity 16 (8⋅2) 73 (8⋅4) 90 (10⋅9) 197 (10⋅1) 249 (14⋅2) <0⋅001
Postoperative bile leakage 5 (2⋅6) 28 (3⋅2) 27 (3⋅3) 67 (3⋅4) 111 (6⋅3) < 0⋅001
Postoperative haemorrhage 2 (1⋅0) 7 (0⋅8) 11 (1⋅3) 19 (1⋅0) 27 (1⋅5) < 0⋅001
Postoperative liver failure 2 (1⋅0) 11 (1⋅3) 9 (1⋅1) 34 (1⋅7) 48 (2⋅7) 0⋅016
Death 2 (1⋅0) 12 (1⋅4) 11 (1⋅3) 32 (1⋅6) 57 (3⋅3) < 0⋅001
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). †χ2 or Fisher’s exact test, except ‡Kruskal–Wallis test.
within 30 days after surgery were scored and graded
according to the Clavien–Dindo classification16. Major
morbidity was defined as the presence of a grade IIIA or
higher complication. A complicated postoperative course
was defined by: hospital stay exceeding 14 days, major
morbidity or death. Postoperative mortality was defined
as death in hospital or within 30 days after surgery; 90-day
mortality was not included in the audit.
Statistical analysis
Categorical variables are shown as numbers with per-
centages, and differences between these variables were
tested using χ2 or Fisher’s exact test. Continuous variables
are presented as median (i.q.r.), unless indicated other-
wise, with differences tested using Mann–Whitney U or
Kruskal–Wallis test. Univariable and multivariable logis-
tic regression analyses were used to identify factors associ-
ated with outcomes. Variables associated with the outcome
(P< 0⋅100,Wald test) in univariable analysis were included
in a multivariable model. Backward selection was used in
order to obtain a parsimonious model. Multivariable ana-
lyses for major morbidity and mortality were conducted on
the entire cohort. The analysis for major morbidity was
repeated in the subgroups of minor liver resection, major
liver resection, and resection for colorectal livermetastases.
Multicollinearity was assessed in all models by calculation
of the variance inflation factor (VIF). A VIF of 2⋅5 is equiv-
alent to an R2 of 0⋅6 between two variables, and correla-
tions with a VIF above 2⋅5 were considered troublesome.
Sensitivity analyses were performed for every multivariable
model to determine the dependency of the model outcome
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Fig. 1 Major morbidity and mortality according to mean centre volume in the Dutch Hepato Biliary Audit between 2014 and 2017
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on specific variables. The analyses were repeated with the
inclusion of additional parameters: centre volume of major
liver resections (more than 10 procedures), and the year
of surgery. P< 0⋅050 was considered to indicate statistical
significance. All analyses were performed using R (R Foun-
dation for Statistical Computing, Vienna, Austria).
Results
Liver surgery in the Netherlands
A total of 6094 procedures were undertaken. Seventy-four
extrahepatic biliary resections and 267 procedures for
unresectable tumours were excluded. A further 163 pro-
cedures were excluded owing to missing essential data.
Finally, 5590 procedures were included in the analyses.
These procedures were done across 34 centres with a
median of 35 (i.q.r. 20–69) annually. Overall, 13⋅7 per cent
of the patients had a complicated postoperative course. The
major morbidity rate was 11⋅2 per cent and the postop-
erative mortality rate was 2⋅0 per cent. The postoperative
course was complicated after 9⋅2 per cent of the 4210minor
liver resections, and major morbidity and mortality rates in
these patients were 7⋅8 and 1⋅2 per cent respectively. After
1380 major liver resections, 26⋅0 per cent of patients had a
complicated postoperative course; themajormorbidity rate
was 20⋅8 per cent and the mortality rate 5⋅9 per cent.
An increase in the rate of adverse events was observed
in higher-volume centres in the overall cohort (Table 1 and
Fig. 1). Of all 1062 resections performed in centres with
fewer than 40 resections per year, 816 (76⋅8 per cent) were
minor resections for colorectal liver metastases (CRLMs)
or benign lesions, and only 21 (2⋅0 per cent) were major
resections for hepatocellular carcinoma (HCC) or biliary
tumours.
Outcomes according to disease subgroups
Table 2 shows morbidity and mortality rates according to
indication for liver surgery. For minor liver resections,
morbidity and mortality rates were similar across different
volume centres for most diagnoses.
Morbidity and mortality for biliary tumours subdivided
according to tumour location are shown in Table 2. Mor-
bidity andmortality rates were highest for perihilar cholan-
giocarcinoma (47⋅0 and 14⋅0 per cent respectively).
The 550 resections forHCCover 4 years were performed
across 22 centres, with 20 centres still undertaking HCC
resections in 2017. The 273 resections for biliary tumours
were carried out in 16 centres. Fourteen centres performed
resections for perihilar and intrahepatic cholangiocarci-
noma.
Multivariable analyses
Although the odds ratio for major morbidity and mor-
tality was significantly higher for centres undertaking at
least 80 liver resections annually compared with those per-
forming 20–39 procedures in univariable analyses, there
was no hospital volume–outcome relationship in multi-
variable analyses for major morbidity and mortality in the
overall cohort after correction for other confounding vari-
ables (Table 3; Table S1, supporting information). The mul-
tivariable analyses for major morbidity and mortality were
repeated for minor resection only (Table S2, supporting
information), major resections (Table S3, supporting infor-
mation) and resections for CRLMs (Table S4, supporting
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Table 2 Tumour-specific major morbidity and mortality rate after major and minor liver resections, and liver resection for biliary
tumours according to hospital volume in the Dutch Hepato Biliary Audit between 2014 and 2017
Hospital volume (annual no. of liver resections)
<20 20–39 40–59 60–79 ≥80 Overall
Minor liver resection
Colorectal liver metastases
No. of procedures 141 605 463 1057 751 3017
Morbidity (%) 7⋅1 7⋅4 7⋅6 6⋅9 9⋅5 9⋅1
Mortality (%) 0⋅7 0⋅3 0⋅6 0⋅6 1⋅2 1⋅4
Non-colorectal liver metastases
No. of procedures 8 32 44 129 122 335
Morbidity (%) 0 6 14 8⋅5 4⋅1 7⋅1
Mortality (%) 0 0 0 0 0 0⋅3
Benign tumour
No. of procedures 15 55 31 154 148 403
Morbidity (%) 7 9 3 7⋅8 6⋅1 6⋅9
Mortality (%) 0 0 0 0⋅6 0 0⋅2
Hepatocellular carcinoma
No. of procedures 3 31 36 136 134 340
Morbidity (%) 0 3 22 7⋅4 11⋅2 10⋅0
Mortality (%) 0 0 6 0 3⋅0 2⋅1
Major liver resection
Colorectal liver metastases
Number 25 118 186 247 253 829
Morbidity (%) 16 25⋅4 11⋅8 16⋅2 17⋅8 15⋅4
Mortality (%) 0 6⋅8 0⋅5 4⋅0 4⋅7 3⋅7
Non-colorectal liver metastases
No. of procedures 3 2 17 17 28 67
Morbidity (%) 0 50 18 24 27 24
Mortality (%) 0 0 6 6 7 5⋅9
Benign tumour
No. of procedures 0 3 11 36 66 116
Morbidity (%) – 0 36 19 23 10⋅2
Mortality (%) – 0 0 3 0 0⋅9
Hepatocellular carcinoma
No. of procedures 1 5 19 65 120 210
Morbidity (%) 100 0 16 20 25⋅0 22⋅4
Mortality (%) 100 0 16 8 9⋅2 9⋅5
Liver resection for biliary tumours
Overall
No. of procedures 0 15 15 112 131 273
Morbidity (%) – 13 53 24⋅1 38⋅9 32⋅2
Mortality (%) – 0 7 7⋅1 14⋅5 10⋅3
Perihilar
No. of procedures 0 1 3 46 50 100
Morbidity (%) – 0 100 33 58 47⋅0
Mortality (%) – 0 0 11 18 14⋅0
Intrahepatic
No. of procedures 0 5 4 44 44 97
Morbidity (%) – 20 50 16 34 26
Mortality (%) – 0 25 2 18 10
Extrahepatic / unspecified
No. of procedures 0 9 8 22 37 76
Morbidity (%) – 11 38 23 19 21
Mortality (%) – 0 0 9 5 5
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Table 3 Univariable and multivariable logistic regression analyses for factors associated with major morbidity including hospital
volume in the Dutch Hepato Biliary Audit between 2014 and 2017
Univariable analysis Multivariable analysis
No. of patients Odds ratio P Odds ratio P
Age (years) <0⋅001 <0⋅001
≤70 3811 1⋅00 (reference) 1⋅00 (reference)
>70 1759 1⋅22 (1⋅03, 1⋅45) 1⋅12 (0⋅93, 1⋅39)
Missing* 20
Sex 0⋅026 0⋅221
M 3175 1⋅00 (reference) 1⋅00 (reference)
F 2399 0⋅67 (0⋅57, 0⋅80) 0⋅63 (0⋅53, 0⋅78)
Missing* 16
ASA fitness grade <0⋅001 <0⋅001
I–II 4388 1⋅00 (reference) 1⋅00 (reference)
≥ III 1023 1⋅86 (1⋅53, 2⋅25) 1⋅77 (1⋅39, 2⋅15)
Missing* 179
Charlson co-morbidity index score <0⋅001 0⋅002
0–1 3909 1⋅00 (reference) 1⋅00 (reference)
≥2 1495 1⋅53 (1⋅28, 1⋅82) 1⋅44 (1⋅14, 1⋅74)
Missing* 186
BMI (per kg/m2) 1⋅00 (0⋅98, 1⋅02) 0⋅963
Liver co-morbidity 0⋅029 0⋅998
No 5043 1⋅00 (reference) 1⋅00 (reference)
Yes 225 1⋅51 (1⋅03, 2⋅15) 1⋅01 (0⋅63, 1⋅56)
Missing* 322
Previous resection 0⋅721
No 4620 1⋅00 (reference)
Yes 772 0⋅96 (0⋅74, 1⋅21)
Missing* 198
Type of tumour <0⋅001 <0⋅001
CRLM 3846 1⋅00 (reference) 1⋅00 (reference)
Other liver metastasis 402 1⋅06 (0⋅74, 1⋅48) 0⋅725 1⋅03 (0⋅69, 1⋅48) 0⋅889
Benign 519 1⋅12 (0⋅82, 1⋅50) 0⋅470 1⋅48 (1⋅01, 2⋅09) 0⋅044
HCC 550 1⋅66 (1⋅28, 2⋅14) <0⋅001 1⋅20 (0⋅92, 1⋅74) 0⋅147
Cholangiocarcinoma 273 4⋅58 (3⋅46, 6⋅02) <0⋅001 3⋅61 (2⋅60, 3⋅03) <0⋅001
Preoperative chemotherapy 0⋅367
No 4062 1⋅00 (reference)
Yes 1124 0⋅91 (0⋅73, 1⋅12)
Missing* 404
Procedure 0⋅185
Resection 4732 1⋅00 (reference)
Resection and ablation 858 0⋅90 (0⋅76, 1⋅05)
Missing* 0
Surgical approach <0⋅001 <0⋅001
Open 4141 1⋅00 (reference) 1⋅00 (reference)
Laparoscopic 1102 0⋅40 (0⋅30, 0⋅53) <0⋅001 0⋅57 (0⋅42, 0⋅78) <0⋅001
Conversion to open 206 0⋅82 (0⋅51, 1⋅26) 0⋅394 0⋅86 (0⋅50, 1⋅37) 0⋅532
Missing* 141
Major resection <0⋅001 <0⋅001
No 4107 1⋅00 (reference) 1⋅00 (reference)
Yes 1380 3⋅10 (2⋅60, 3⋅68) 2⋅47 (2⋅02, 3⋅03)
Missing* 103
© 2020 The Authors. British Journal of Surgery published by John Wiley & Sons Ltd www.bjs.co.uk BJS
on behalf of BJS Society Ltd.
Volume–outcome in liver surgery
Table 3 Continued
Univariable analysis Multivariable analysis
No. of patients Odds ratio P Odds ratio P
Simultaneous other resection <0⋅001 <0⋅001
No 2713 1⋅00 (reference) 1⋅00 (reference)
Yes 886 1⋅60 (1⋅28, 2⋅00) <0⋅001 1⋅57 (1⋅20, 2⋅05) <0⋅001
Missing* 1991 1⋅23 (1⋅02, 1⋅48) 0⋅031 1⋅14 (0⋅92, 1⋅42) 0⋅238
Simultaneous colorectal resection 0⋅002 <0⋅001
No 4883 1⋅00 (reference) 1⋅00 (reference)
Yes 523 1⋅50 (1⋅15, 1⋅92) 2⋅01 (1⋅47, 2⋅73)
Missing* 184
Type of hospital <0⋅001 0⋅914
Tertiary referral centre 3057 1⋅00 (reference) 1⋅00 (reference)
Other 2533 0⋅63 (0⋅53, 0⋅75) 0⋅98 (0⋅71, 1⋅36)
Annual hospital volume <0⋅001 0⋅163
20–39 866 1⋅00 (reference) 1⋅00 (reference)
<20 196 0⋅90 (0⋅51, 1⋅49) 0⋅692 0⋅82 (0⋅45, 1⋅44) 0⋅524
40–59 822 1⋅26 (0⋅93, 1⋅71) 0⋅143 1⋅16 (0⋅81, 1⋅67) 0⋅412
60–79 1953 1⋅11 (0⋅83, 1⋅49) 0⋅485 1⋅05 (0⋅73, 1⋅53) 0⋅783
≥80 1753 1⋅67 (1⋅22, 2⋅02) <0⋅001 1⋅41 (0⋅91, 2⋅19) 0⋅121
Values in parentheses are 95 per cent confidence intervals. *Not included in multivariable analysis. CRLM, colorectal liver metastasis; HCC, hepatocellular
carcinoma.
information). None of these analyses demonstrated a hos-
pital volume–outcome effect. Multicollinearity was not a
problem as the VIF was below 2⋅5 for all variables in all
models. Sensitivity analyses were undertaken for all out-
comes stratified by tumour type. In addition, all logistic
regression analyses were performed with addition of a vari-
able concerning annual major resection volume (more than
10) and with addition of a variable correcting for year of
surgery. These variables were not significant predictors of
outcomes and did not alter the results of the multivariable
models.
Oncological margins
The association between hospital volume and oncologi-
cal margin was investigated (Table S5, supporting infor-
mation). Negative margins were achieved in 3251 patients
with CRLMs (84⋅5 per cent), with more frequent posi-
tive resection margins in the higher-volume centres. These
results are likely to be explained by more advanced disease
in these patients, as demonstrated bymultivariable analyses
that identified five or more metastases (odds ratio 1⋅57, 95
per cent c.i. 1⋅08 to 2⋅26) and major liver resection (odds
ratio 1⋅37, 1⋅07 to 1⋅75) as predictors of positive margins.
Centre volume was not significant in multivariable analy-
sis. Positive margins were most frequent after resection of
biliary tumours, and in particular in lower-volume centres
after resection of perihilar and intrahepatic cholangiocar-
cinoma (Table S5, supporting information).
Discussion
In the Dutch setting, no association between hospital vol-
ume and morbidity or mortality was observed after liver
surgery. Although there is no evidence base for the cur-
rent cut-off of 20 procedures, all data were gathered after
the implementation of this current guideline and the data
do not support the implementation of any lower, or need
for a higher, procedure volume cut-off. The lack of a
volume–outcome relationship is likely to be explained by
the existing advanced patient selection across lower- and
higher-volume centres in regional collaboration. There
remains room for improvement in resections for HCC and
biliary tumours. Reduction in the number of centres cur-
rently involved in treating HCC and biliary tumours to a
few dedicated centres might help to improve outcomes for
these high-risk patients.
Few nationwide analyses reporting on morbidity and
mortality after liver resection are available, and data on
hospital volume are scarce. A French nationwide study17
that included 28 708 liver resections over 4 years reported
a 90-day mortality rate of 3⋅2 per cent. There was a median
of four resections per centre and 20 per cent of patients
had surgery in centres with a case volume below ten annual
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procedures. In multivariable analyses, a volume–mortality
association was observed, with centres undertaking five or
fewer procedures annually as a reference. The hazard ratios
for mortality were similar for all hospital categories under-
taking more than 11 procedures annually, demonstrating
no further volume–outcome relationship above the cut-off
of 11 resections. In a large, but not nationwide, report
from the USA including 11 429 patients, the overall 90-day
mortality rate was 4⋅9 per cent, but ranged from 7⋅1 per
cent when the hospital volume was below ten procedures
annually to 2⋅9 per cent when at least 50 procedures were
done18. In another report19, the analyses were based on a
similar data set including 2949 liver resections, with the
same 4⋅9 per cent mortality rate. The authors concluded
that only resections done in high-volume centres, by a
high-volume surgeon, were associated with reduced mor-
tality. The median hospital volume was low, with two pro-
cedures annually, andmedian surgeon volume was one. In a
more recent nationwide analysis20, including 110 332 liver
resections performed across 1136 German hospitals, the
overall mortality rate was 5⋅8 per cent. There is no central-
ization in Germany. For major liver resections, mortality
was lower in centres undertaking at least 44 major resec-
tions annually. Although overall centre volume was not
reported, the 1136 hospitals active in liver surgery suggest
that median centre volume is low; of centres performing
major resections, 80 per cent undertook fewer than four
major hepatectomies annually. In this German report, the
mortality rate was high in specific subgroups, such as 16
per cent after extended hepatectomy and 26 per cent when
combined with biliary reconstruction.
Available studies that reported on the volume–outcome
relationship in liver surgery and showed lower mortal-
ity rates in high-volume centres had low median hospital
volumes of two to four procedures annually. The Dutch
volume requirement of 20 liver resections annually is sim-
ilar to that in several other countries21,22. The mortality
rates reported in series that used the 20-procedure volume
requirement (such as 2⋅0 per cent in the Netherlands and
2⋅1 per cent in Norway21) are lower than those in coun-
tries that have not implemented such a cut-off: 3⋅2 per cent
in France17, 4⋅9 per cent in America18,19, 5⋅8 per cent in
Germany20 and 3⋅1 per cent in Sweden23. Such direct com-
parisons are biased by numerous factors including different
inclusion criteria, definitions and cohort characteristics.
There are several possible reasons for the lack of a
volume–outcome relationship in the present cohort. First,
there simply might not be a volume–outcome relationship
in liver surgery after setting a threshold of 20 resections
annually, and above this threshold outcomes are just as
favourable in the smaller-volume as in the higher-volume
centres. A more likely explanation could be the higher
median hospital volume of 35 procedures than in other
studies, and the advanced risk stratification already per-
formed across many Dutch regional collaborations. This is
demonstrated by the predominance of minor liver resec-
tions for CRLMs in the lowest-volume centres, com-
pared with increasing numbers of major liver resections
for other indications in the higher-volume centres. The
data also indicate more advanced metastatic disease in
higher-volume centres, and that the majority of HCC and
biliary cancers are treated in the largest centres.
Although the mortality rate of 2⋅0 per cent appears
to be in the lower range of rates reported in literature,
there are several areas for improvement. The mortality
rate after major liver resection was 5⋅9 per cent overall
and 3⋅7 per cent for CRLMs. These rates have led to
the start of a detailed analysis of these fatalities, includ-
ing failure-to-rescue parameters. This project aims to fur-
ther improve stratification of patients across centres and
reduce overall the mortality rate to below 1 per cent. The
current Dutch guideline encourages referral of patients
with HCC and biliary cancers to experienced centres; how-
ever, in 2017, 20 and 16 centres undertook surgery on
HCC and biliary tumours respectively. The overall mor-
tality rates of 4⋅9 per cent after HCC resection and up to
9⋅5 per cent after major resection are higher than rates in
the largest international series from expert centres (0⋅8–2⋅9
per cent)24–26. For biliary tumours, the overall mortality
rate was 10⋅3 per cent, with the highest rate for perihilar
cholangiocarcinoma (14⋅0 per cent). Although this is con-
sistent with an in-hospital mortality rate of 13 per cent
in a meta-analysis27 of Western series, there is significant
room for improvement considering that the mortality rate
after perihilar cholangiocarcinoma resections in Asian cen-
tres is usually below 4 per cent27. In addition, margins were
positive after biliary cancer resection in over one-third of
all patients. Considering these rates, the treatment of this
relatively small group across 16–20 centres is unlikely to
optimize the outcomes, and further centralization of these
resections to a handful of dedicated centres might help to
reduce adverse outcomes.
This study had several limitations. It is possible that the
lack of a volume–outcome relationship in the present ana-
lysis was the result of one or more risk-stratifying vari-
ables that were not included in the nationwide audit data
set. These variables could include advanced data on (hep-
atic) co-morbidity, or variables in the patient evaluation
such as the assessment of remnant liver volume and func-
tion. As in other national audits, there are some missing
data for non-mandatory parameters28,29. Furthermore, to
ensure complete anonymity in the analysis from a small
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country such as the Netherlands, no distinction was made
between hospitals’ teaching status, which is a factor known
to have a potential influence on outcomes30. Althoughmost
perioperative deaths are likely captured by the 30-day or
in-hospital mortality variable, 90-day mortality is likely
more representative of true mortality, but is not included in
the audit and was not therefore not available for the present
study31. As the DHBA was designed for analysis of peri-
operative outcomes, no information regarding long-term
outcomes is collected and therefore these could not be
included in the analyses.
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Editor’s comments
This study did not find a volume–outcome relationship for liver surgery in the Netherlands, despite that the
relationship is well evidenced for many low-volume, high-risk procedures. This study is novel because it shows
what happens after centralization of specialist liver surgery into units performing at least 20 procedures: outcomes
are broadly similar. The Dutch should be congratulated on proving centralization works. The key now is to define
the minimum procedure number to achieve this for each operation, which may vary depending on complexity. Also,
centralization should be encouraged.
J. J. Earnshaw
Editor-in-Chief, BJS
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